Cabaletta Bio Files 8-K
Ticker: CABA · Form: 8-K · Filed: Mar 20, 2024 · CIK: 1759138
Sentiment: neutral
Topics: sec-filing, 8-k, reporting
Related Tickers: CABO
TL;DR
Cabaletta Bio filed a routine 8-K, no major news.
AI Summary
Cabaletta Bio, Inc. filed an 8-K on March 20, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing indicates Cabaletta Bio is adhering to its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — This is a standard SEC filing with no new material information that would immediately impact the company's risk profile.
Key Players & Entities
- Cabaletta Bio, Inc. (company) — Registrant
- 2929 Arch Street, Suite 600, Philadelphia, PA 19104 (location) — Principal executive offices
- March 20, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Cabaletta Bio, Inc.?
The primary purpose is to report on Regulation FD Disclosure and Financial Statements and Exhibits, as indicated by the filing's item information.
When was this 8-K filing submitted?
The filing was submitted on March 20, 2024.
What is Cabaletta Bio, Inc.'s principal executive office address?
The principal executive offices are located at 2929 Arch Street, Suite 600, Philadelphia, PA 19104.
What is Cabaletta Bio, Inc.'s state of incorporation?
Cabaletta Bio, Inc. is incorporated in Delaware.
Does this 8-K filing contain specific financial results or material event disclosures?
Based on the provided text, this 8-K filing is primarily for standard reporting items (Regulation FD Disclosure, Financial Statements and Exhibits) and does not detail specific financial results or material events.
Filing Stats: 532 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-03-20 07:11:55
Key Financial Figures
- $0.00001 — ich Registered Common Stock, par value $0.00001 per share CABA The Nasdaq Global Se
Filing Documents
- d812029d8k.htm (8-K) — 25KB
- d812029dex991.htm (EX-99.1) — 16KB
- g812029g0320024612707.jpg (GRAPHIC) — 3KB
- 0001193125-24-072048.txt ( ) — 174KB
- caba-20240320.xsd (EX-101.SCH) — 3KB
- caba-20240320_lab.xml (EX-101.LAB) — 18KB
- caba-20240320_pre.xml (EX-101.PRE) — 11KB
- d812029d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release issued by the registrant on March 20, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CABALETTA BIO, INC. Date: March 20, 2024 By: /s/ Steven Nichtberger Steven Nichtberger, M.D. President and Chief Executive Officer